Medical writer: Jasenka Piljac Žegarac, PhD
Several experts discussed the current challenges in the use of immunotherapy in non–small cell lung cancer (NSCLC)—the most common type of lung cancer—as well as strategies to overcome them, in the Interactive Case-Based Session “Challenges in Use of Immunotherapy in NSCLC: Where the Rubber Meets the Road,” held May 31. The session was chaired by Jyoti D. Patel, MD, FASCO, of the University of Chicago Medical Centre.
“The objectives are to understand the factors that affect the risk/benefit ratio of treatment with immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC and to understand what challenges this poses in patients with dysregulated immunity, chiefly those with autoimmune diseases,” Dr. Patel said.
She further noted that it is important to understand: (1) how the data hold up in patients encountered in the clinic and not just those enrolled in clinical trials; (2) which patients are to...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Neoadjuvant Chemotherapy as a Potential Treatment Option in Colon Cancer Next Article
Endocrine Therapy plus Ribociclib Yields Overall Survival Advantage in HR+/HER2-negative Breast Cancer »
Table of Contents: ASCO 2019
Head and Neck Cancer
Genitourinary Cancer - Prostate Cancer
Developmental Therapeutics - Immunotherapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.